全文获取类型
收费全文 | 307篇 |
免费 | 15篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 43篇 |
妇产科学 | 1篇 |
基础医学 | 78篇 |
口腔科学 | 1篇 |
临床医学 | 51篇 |
内科学 | 55篇 |
皮肤病学 | 4篇 |
神经病学 | 6篇 |
特种医学 | 13篇 |
外科学 | 10篇 |
综合类 | 9篇 |
预防医学 | 14篇 |
眼科学 | 1篇 |
药学 | 21篇 |
中国医学 | 2篇 |
肿瘤学 | 12篇 |
出版年
2022年 | 6篇 |
2021年 | 6篇 |
2020年 | 8篇 |
2019年 | 8篇 |
2018年 | 5篇 |
2016年 | 5篇 |
2015年 | 7篇 |
2014年 | 11篇 |
2013年 | 7篇 |
2012年 | 9篇 |
2011年 | 4篇 |
2010年 | 13篇 |
2009年 | 9篇 |
2008年 | 5篇 |
2007年 | 7篇 |
2006年 | 5篇 |
2005年 | 8篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 7篇 |
1995年 | 5篇 |
1993年 | 7篇 |
1992年 | 3篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 4篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1979年 | 5篇 |
1976年 | 3篇 |
1975年 | 10篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1972年 | 6篇 |
1971年 | 6篇 |
1970年 | 4篇 |
1969年 | 5篇 |
1967年 | 4篇 |
1966年 | 2篇 |
1965年 | 3篇 |
排序方式: 共有324条查询结果,搜索用时 31 毫秒
1.
A P Rodionov V V Lyskovtsev N A Ignatova E A Tolmacheva E K Grigor'eva G F Belinskiaia B V She?nberg 《Farmakologiia i toksikologiia》1990,53(3):40-43
The pharmacokinetics and pharmacodynamics of bonnecor were studied simultaneously in animals with experimental arrhythmia. It was shown that irrespective of the animal species and individual features of the drug elimination kinetics the level of bonnecor concentration correlated with the antiarrhythmic effect. The data on the excretion of bonnecor and its metabolites in the urine in the dog and man were obtained. The decrease of bioavailability at oral administration of bonnecor was demonstrated to be related to its intensive conversion in metabolite M-I. 相似文献
2.
3.
4.
Mikael F. Forsgren Patrik Nasr Markus Karlsson Nils Dahlström Bengt Norén Simone Ignatova 《Scandinavian journal of gastroenterology》2020,55(7):848-859
Abstract
Background and aims
Accurate biomarkers for quantifying liver fibrosis are important for clinical practice and trial end-points. We compared the diagnostic performance of magnetic resonance imaging (MRI), including gadoxetate-enhanced MRI and 31P-MR spectroscopy, with fibrosis stage and serum fibrosis algorithms in a clinical setting. Also, in a subset of patients, MR- and transient elastography (MRE and TE) was evaluated when available. 相似文献5.
Zemlyanova M. A. Zaitseva N. V. Ignatova A. M. Stepankov M. S. Toropov L. I. Kol’dibekova Yu. V. 《Bulletin of experimental biology and medicine》2021,170(5):665-668
Bulletin of Experimental Biology and Medicine - In female Wistar rats, we studied the effects of daily 20-day administration of intragastric suspension of nanosized calcium oxide on hematological... 相似文献
6.
目的 建立一种快速、灵敏的高效液相色谱-串联质谱(HPLC-MS/MS)方法以测定人血浆中对乙酰氨基酚浓度,并应用于两种对乙酰氨基酚制剂的人体药代动力学和生物等效性研究。方法 以替硝唑为内标,200μL血浆样品经5倍于其体积的乙酸乙酯液液萃取,再经Waters XBridge? C18柱等度洗脱分离后导入串联质谱,以正离子多反应监测模式进行定量分析,对乙酰氨基酚和内标的选择性反应离子对分别是m/z 152→110和248→121。方法经验证后应用于19名健康受试者单剂量空腹口服两种对乙酰氨基酚制剂500mg后药代动力学和生物等效性的研究。结果 血浆中对乙酰氨基酚在0.1~8.0 μg·mL-1范围内线性良好(r2 > 0.99),最低检测限为 0.1 μg·mL-1,提取回收率为91.0%~98.7%,日内和日间准确度分别为98.8%~111.3% (精密度:CV ? 9.03%)和94.9%~102.6% (精密度:CV ? 10.68%)。生物等效性试验中,受试制剂与参比制剂的主要药代动力学参数Cmax、AUC0-t和AUC0-∞ 几何均值比的90%置信区间分别为83.50%~105.79%,94.25%~101.54%和93.24%~101.02%,均落在生物等效可接受标准80.00%~125.00%范围内。结论 所建立测定人血浆中对乙酰氨基酚浓度的HPLC-MS/MS法具有快速灵敏、回收率高、选择性好的特点,适用于对乙酰氨基酚片人体药代动力学和生物等效性研究。受试制剂与参比制剂在人体内吸收速度和程度相似,两种制剂生物等效。 相似文献
7.
8.
9.
Adhesion of platelets to surface-bound fibrinogen under flow 总被引:2,自引:2,他引:2
After platelet activation, fibrinogen mediates platelet-platelet interactions leading to platelet aggregation. In addition, fibrinogen can also function as a cell adhesion molecule, providing a substratum for adhesion of platelets and endothelial cells. In this report, we studied the adhesion of platelets to surface-immobilized fibrinogen under flow in different shear rates. Heparinized whole blood containing mepacrine-labeled platelets was perfused for two minutes at various wall shear rates from 250 to 2,000 s-1 in a parallel plate flow chamber. The number of adherent fluorescent platelets was quantitated every 15 seconds with an epifluorescent videomicroscope and digital image processing system. When compared with platelet adhesion and aggregation seen on glass surfaces coated with type I bovine collagen, a significant increase in platelet adhesion was observed on immobilized fibrinogen up to wall shear rates of 800 s-1. The adherent platelets formed a single layer on fibrinogen-coated surfaces. Under identical conditions, no significant adhesion was observed on fibronectin- or vitronectin-coated surfaces. Although platelet adhesion to collagen was substantially inhibited by the platelet inhibitors prostaglandin E1 and theophylline, these inhibitors had no effect on platelet adhesion to fibrinogen. Platelets adhered to recombinant homodimeric wild-type (gamma 400-411) fibrinogen, but not to the recombinant homodimeric gamma' variant of fibrinogen. Platelet adhesion to recombinant fibrinogen with RGD to RGE mutations at positions alpha 95-97 and alpha 572-574 was similar to that with plasma-derived fibrinogen. These results show that platelets adhere to fibrinogen-coated surfaces under moderate wall shear rates, that the interaction is mediated by the fibrinogen 400-411 sequence at the carboxy-terminus of the gamma chain, and that the interaction is independent of platelet activation and the RGD sequences in the alpha chain. 相似文献
10.
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation 总被引:7,自引:10,他引:7
Epstein-Barr virus-induced lymphoproliferative disease (EBV-LPD) is a potentially lethal complication during the first 6 months after allogeneic bone marrow transplantation (BMT). To determine whether deficiencies of EBV-specific cellular immunity contribute to EBV-LPD susceptibility and distinguish patients at risk, we performed limiting dilution analysis to quantify anti-EBV cytotoxic T-lymphocyte precursor (CTLp) frequencies in 26 recipients of unmodified or T-cell-depleted (TCD) grafts from EBV-seropositive donors. At 3 months post-BMT (n = 26), only five patients had EBV CTLp frequencies in the range of seropositive normal controls, irrespective of the type of transplant administered. By 6 months post-BMT, 9 of 13 patients tested had EBV CTLp frequencies within the normal range. The time period in which these patients had deficient cellular immunity to EBV corresponds to the period in which we have observed EBV-LPD in most prior patients. One patient with a low EBV CTLp frequency at 4 months post-BMT developed an EBV-LPD. Within 2 weeks of receiving an infusion of donor peripheral blood mononuclear cells (PBMC) providing less than 1,200 EBV- specific cytotoxic T-cell precursors, populations of EBV-specific CTL in the circulation were restored to levels detected in normal seropositive adults. Concurrently, the patient achieved a regression of the EBV-LPD, which has been sustained without further therapy. These studies indicate that recipients of both unmodified and TCD marrow grafts have profound deficiencies of EBV-specific T cell-mediated immunity early posttransplant, and that the period of risk for EBV-LPD closely corresponds to this interval of severe deficiency. Treatment of one patient with EBV-LPD with marrow donor-derived PBMC induced a rapid expansion of EBV-specific cytotoxic T-cell populations that occurred contemporaneously with the clinical regression of disease. 相似文献